Glenmark Chief Bullish Despite Generic Zetia's Poor US Start

Glenmark Pharmaceuticals reported overall growth in the fourth quarter of 2016-17, but investors bludgeoned the company’s shares on concerns around the slow traction of generic Zetia in the US and a sharp decline in earnings on a sequential basis.

Eclipse
Ezetimibe's Weak US Launch Eclipsed Glenmark's Bullish Outlook • Source: Shutterstock

Shares of Glenmark Pharmaceuticals Ltd. were battered on Indian bourses on May 12, amid concerns over the slow pick-up in generic Zetia (ezetimibe) sales in the US and a sharp fall in profits in the fourth quarter ended March 2017 on a sequential basis. Glenmark and its partner, Endo, have 180 days of exclusivity for generic ezetimibe.

Glenmark’s chair and managing director, Glenn Saldanha, said that the US business had a “tough” fourth quarter where price erosion...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.